CN116987091A - 用于治疗癫痫发作疾病的药物及其制备方法 - Google Patents
用于治疗癫痫发作疾病的药物及其制备方法 Download PDFInfo
- Publication number
- CN116987091A CN116987091A CN202310950772.0A CN202310950772A CN116987091A CN 116987091 A CN116987091 A CN 116987091A CN 202310950772 A CN202310950772 A CN 202310950772A CN 116987091 A CN116987091 A CN 116987091A
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- pharmaceutically acceptable
- solvate
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 17
- 206010015037 epilepsy Diseases 0.000 title claims abstract description 17
- 206010010904 Convulsion Diseases 0.000 title abstract description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract description 4
- 208000028329 epileptic seizure Diseases 0.000 title abstract description 4
- 238000002360 preparation method Methods 0.000 title abstract description 4
- 229940079593 drug Drugs 0.000 title description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 29
- 150000003839 salts Chemical class 0.000 claims description 13
- 239000012453 solvate Substances 0.000 claims description 13
- -1 hydroxy, amino Chemical group 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 4
- 239000004327 boric acid Substances 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 239000000460 chlorine Substances 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 2
- 238000005859 coupling reaction Methods 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- AZEZEAABTDXEHR-UHFFFAOYSA-M sodium;1,6,6-trimethyl-10,11-dioxo-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-2-sulfonate Chemical group [Na+].C12=CC=C(C(CCC3)(C)C)C3=C2C(=O)C(=O)C2=C1OC(S([O-])(=O)=O)=C2C AZEZEAABTDXEHR-UHFFFAOYSA-M 0.000 abstract description 19
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 abstract description 12
- HYXITZLLTYIPOF-UHFFFAOYSA-N Tanshinone II Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)=CO2 HYXITZLLTYIPOF-UHFFFAOYSA-N 0.000 abstract description 4
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N tanshinone IIA Natural products C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 abstract description 4
- 230000006378 damage Effects 0.000 abstract description 2
- 230000006870 function Effects 0.000 abstract description 2
- 210000005036 nerve Anatomy 0.000 abstract description 2
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 29
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 230000001037 epileptic effect Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 229940125904 compound 1 Drugs 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 238000004821 distillation Methods 0.000 description 6
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 229940125782 compound 2 Drugs 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 210000003414 extremity Anatomy 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000005809 status epilepticus Diseases 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- XWLUWCNOOVRFPX-UHFFFAOYSA-N Fosphenytoin Chemical compound O=C1N(COP(O)(=O)O)C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 XWLUWCNOOVRFPX-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 206010028347 Muscle twitching Diseases 0.000 description 2
- 101001024685 Pandinus imperator Pandinin-2 Proteins 0.000 description 2
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 229960000693 fosphenytoin Drugs 0.000 description 2
- 230000000971 hippocampal effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 150000002611 lead compounds Chemical class 0.000 description 2
- 230000013016 learning Effects 0.000 description 2
- 229960004002 levetiracetam Drugs 0.000 description 2
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 230000015654 memory Effects 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 2
- 229960002036 phenytoin Drugs 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229940102566 valproate Drugs 0.000 description 2
- 230000031836 visual learning Effects 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009346 Clonus Diseases 0.000 description 1
- BKQVCDGQNOKQNF-KFFVICKMSA-N Corynoxine B Natural products O=C(OC)/C(=C\OC)/[C@@H]1[C@H](CC)C[N+]2[C@H]([C@@]3(C(=O)Nc4c3cccc4)CC2)C1 BKQVCDGQNOKQNF-KFFVICKMSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- VCNYNWHVJKWJRQ-UHFFFAOYSA-N Isorhynchophylline Natural products CCC1=CN2CCC3(C2CC1C(=COC)C(=O)OC)C(=O)Nc4ccccc34 VCNYNWHVJKWJRQ-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000021966 Motor seizure Diseases 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- DAXYUDFNWXHGBE-KAXDATADSA-N Rhynchophylline Chemical compound O=C1NC2=CC=CC=C2[C@@]11CCN2C[C@H](CC)[C@@H](\C(=C/OC)C(=O)OC)C[C@H]21 DAXYUDFNWXHGBE-KAXDATADSA-N 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000002566 clonic effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 239000003257 excitatory amino acid Substances 0.000 description 1
- 230000002461 excitatory amino acid Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 208000018883 loss of balance Diseases 0.000 description 1
- BMQVDVJKPMGHDO-UHFFFAOYSA-K magnesium;potassium;chloride;sulfate;trihydrate Chemical compound O.O.O.[Mg+2].[Cl-].[K+].[O-]S([O-])(=O)=O BMQVDVJKPMGHDO-UHFFFAOYSA-K 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000007087 memory ability Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 150000002742 methionines Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000002610 neuroimaging Methods 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000009323 psychological health Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000009094 second-line therapy Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000006886 spatial memory Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 210000003478 temporal lobe Anatomy 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960004394 topiramate Drugs 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/153—Ortho-condensed systems the condensed system containing two rings with oxygen as ring hetero atom and one ring with nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明提供了用于治疗癫痫发作疾病的药物及其制备方法。所述药物为具有式I结构的丹参酮IIA类似物。本发明的丹参酮IIA类似物能够很好地抑制癫痫,减少发病次数、缩减癫痫持续时间,并且能够降低体内同型半胱氨酸的水平,减少神经功能的损伤。此外,本发明化合物的药理活性优于丹参酮IIA。
Description
技术领域
本发明涉及医药领域,具体来说,本发明涉及一种用于治疗癫痫发作疾病的药物及其制备方法。
背景技术
癫痫是一种常见的神经***疾病,其特征为大脑神经元异常放电引起的脑功能短暂性失常,患者可表现为感觉、运动、意识、精神、行为、自主神经功能障碍或兼有之,对社会、身体和心理健康都存在危害。癫痫的诊断主要以临床为依据,辅助调查包括脑电图和神经成像,其中以磁共振成像为主。第二个判断标准是运动性或非运动性发作症状。第三个判断标准为发作是否有意识障碍。
对于癫痫的一线治疗,美国神经重症监护学会发布的《癫痫持续状态评估和管理指南》、美国癫痫学会发布的《儿童及成人惊厥性癫痫持续状态的治疗》以及中华医学会发布的《非惊厥性癫痫持续状态的治疗专家共识》均推荐首选静脉滴注苯二氮类药物,然而其有效率只有70%左右。对于一线治疗失败的患者,《儿童及成人惊厥性癫痫持续状态的治疗》推荐的二线治疗药物仅限苯妥英(phenytoin,PHT)、磷苯妥英(fosphenytoin,FPHT)、丙戊酸(valproate,VPA)、左乙拉西坦(levetiracetam,LEV)等。但这些药物的副作用难以控制及部分患者不能耐受,且容易引起耐药性癫痫的产生。
中药治疗癫痫具有副作用小且减少癫痫并发症发作的优势,近年来有众多文献报道了中药单体化合物、中药提取物在在治疗癫痫方面的作用,从机理上分,大致包括:1、调控离子通道类,例如钩藤碱(Anticonvulsant effect ofRhynchophylline involved inthe inhibition of persistent sodium current and NMDA receptor current in thepilocarpine rat model of temporal lobe epilepsy.Shao H,et al.Neuroscience,2016,337:355-369)、柴胡皂苷A(Saikosaponin amodulates remodeling of Kv4.2-mediated A-type voltage-gated potassium currents in rat chronic temporallobeepilepsy.Hong Y,etal.Drug Design,Development and Therapy,2018,12:2945-2958)、丹参酮IIA(Tanshinone IIA,a constituent of Danshen,inhibits the release ofglutamate in rat cerebrocortical nerve terminals.Lin T Y,et al.JournalofEthnopharmacology,2013,147(2):488-496)、川芎嗪(Tetramethylpyrazine reducesepileptogenesis progression in electrical kindling models by modulatinghippocampal excitatory neurotransmission.Jin Y,et al.ACS ChemicalNeuroscience,2019,10(12):4854-4863)、天麻素(Gastrodin reduces the severityofstatus epilepticus in the rat pilocarpine model oftemporal lobe epilepsy byinhibiting Nav1.6 sodium currents.Shao H,et al.Neurochemical Research,2017,42(2):360-374)等;2、抗氧化应激类,例如黄芩苷(胡运刚.黄芩苷对海人酸致痫小鼠海马组织HO-1和NQO1表达的影响.福州:福建医科大学硕士学位论文,2015)、红景天苷(Salidroside shows anticonvulsant and neuroprotective effects by activatingthe Nrf2-ARE pathway in a pentylenetetrazol-kindling epileptic model.Wu Y,etal.Brain Research Bulletin,2020,164:14-20)、丹皮酚(Anticonvulsant andneuroprotective effects of paeonol in epileptic rats.Liu D H,etal.Neurochemical Research,2019,44(11):2556-2565.)、大黄素(大黄素对海人酸致痫小鼠海马神经细胞的保护作用.欧阳龙强等.国际神经病学神经外科学杂志,2018,45(5):471-476.)、甘草酸(Glycyrrhizic acid protectsjuvenile epileptic rats againsthippocampal damage through activation of Sirtuin3.Wu G,et al.Brain ResearchBulletin,2020,164:98-106)、牛磺酸(Taurine protects from pentylenetetrazole-induced behavioral and neurochemical changes in Zebrafish.Fontana B D,etal.MolecularNeurobiology,2019,56(1):583-594)等;3、保护神经元细胞,例如金丝桃苷(Hyperoside alleviates epilepsy-induced neuronal damage by enhancingantioxidant levels and reducing autophagy.Cao J,et al.Ethnopharmacol,2020,257:112884)、蝎子的乙醇提取物(Scorpion ethanol extract and valproic acideffects on hippocampal glial fibrillary acidic protein expression in a ratmodel of chronic-kindling epilepsy induced by lithium chloride-pilocarpine.LiangY,et al.Neural Regeneration Research,2012,7(6):426-433)等;4、抑制神经元细胞凋亡,例如人参皂苷(Ginsenoside Rb1 Protects the Brain fromDamage Induced by Epileptic Seizure via Nrf2/ARE Signaling.Shi Y,etal.Cellular Physiology and Biochemistry,2018,45(1):212-225.)、葛根素(葛根素的研究进展.王东红等.西部中医药,2017,30(1):139-142.)、蛇床子素(蛇床子素对海人酸致痫大鼠神经元Caspase-3和Caspase-9蛋白表达的影响.谢洪婷等.中医药信息,2015,32(2):16-18)、石菖蒲挥发油(石菖蒲挥发油抗惊厥作用及对癫痫大鼠海马PKC表达的影响.王坤芳等.中药药理与临床,2015,31(1):97-100)等。
中药单体化合物为探索癫痫的治疗方案提供新思路。
发明内容
本发明的目的是提供一种具有改善的癫痫治疗作用的化合物,所述化合物为丹参酮IIA类似物。
在本发明的一个方面,本发明提供了一种式I化合物或其药学上可接受的盐、溶剂合物:
其中:
X选自CR0、N;
R0表示H、(C1-6)烷基、(C1-6)烷氧基。
R1、R2各自独立地选自H、任选经取代的(C1-6)烷基、任选经取代的(C1-6)烷氧基。
在一个实施方案中,X选自CH。
在一个实施方案中,X选自N。
在一个实施方案中,所述任选经取代是指被选自以下基团中的一个或多个取代或未取代:卤素、羟基、氨基。
在一个实施方案中,R1、R2各自独立地选自H、(C1-4)烷基。
优选的,R1选自H。
优选的,R2选自甲基、乙基。
在一个实施方案中,所述化合物选自:
在本发明中,卤素表示氟、氯、溴或碘。
在本发明中,烷基表示优选含有1-6个碳原子的直链或支链饱和烃基。烷基的实例包括甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、戊基或己基等。
在一个实施方案中,本发明化合物的药学上可接受的盐是指药学上可接受的酸加成盐,包括:盐酸盐、二盐酸盐、氢溴酸盐、磷酸盐、硫酸盐、乙酸盐、二乙酸盐、富马酸盐、马来酸盐、丙二酸盐、琥珀酸盐、酒石酸盐、柠檬酸盐、草酸盐、甲磺酸盐或对甲苯磺酸盐等,但不限于此。
在本发明中,本发明化合物的溶剂合物是指一个或多个溶剂分子与本发明的化合物所形成的缔合物。形成溶剂化物的溶剂包括,但并不限于,水、甲醇、乙醇、异丙醇、二甲亚砜、乙酸乙酯、乙酸、氨基乙醇。
在本发明另一方面,本发明提供了一种药物组合物,其包含至少一种式I化合物或其药学上可接受的盐、溶剂合物。
在一个实施方案中,本发明所述药物组合物可包含一种或更多种药学上可接受的载体。
本发明的药物组合物可以按照标准方式给药用于希望被治疗的病症,例如通过局部、口服、直肠或肠胃外给药。为了实现上述目的,可以将本发明化合物通过本领域已知的方式配制成例如气溶剂、干粉制剂、片剂、胶囊剂、糖浆剂、散剂、颗粒剂、水或油性溶液剂或混悬剂、乳剂、可分散散剂、栓剂、软膏剂、霜剂、滴剂和无菌注射水或油性溶液剂或混悬剂。
根据给药模式,药物组合物可以含有0.05-99wt%,例如0.05-80wt%,例如0.10-70wt%,例如0.10-50wt%活性成分,所有重量百分数基于整个组合物计算。本发明的合适药物组合物适合以单位剂型用于口服给药,例如片剂或胶囊剂形式口服给药,其中每片含有0.1mg-0.2g活性成分。
本发明提供了制备所述组合物的方法,所述方法包括将活性成分与载体混合。
本发明化合物的有效剂量可以根据年龄、体重、性别、给药方法、健康状况和病症严重程度来确定。例如,一个体重70kg的成年人的剂量为0.1-1000mg/天,优选1-500mg/天。这样的给药可以一天一次至多次,根据医生或者药剂师的决定执行。
在本发明另一方面,本发明还提供了式I化合物或其药学上可接受的盐、溶剂合物在制备预防或治疗癫痫的药物中的应用。
在本发明另一方面,本发明还提供了一种制备式I化合物的方法,其包括以下步骤:
将原料a转化为含硼酸酯或硼酸的中间体b,然后与原料c发生偶联反应得到中间体d;中间体d合环成为式I化合物;
其中R1-R2、X如上文所述,Xa、Xb各自独立地选自氯或溴,Ra、Rb各自独立地选自(C1-4)烷基,RB选自
有益效果
本发明提供了用于治疗癫痫发作疾病的药物。本发明以丹参酮IIA作为先导化合物,设计并合成了丹参酮IIA类似物。本发明化合物具有抑制癫痫,减少发病次数、缩减持续时间的作用,并且能够降低体内同型半胱氨酸的水平,减少神经功能的损伤。此外,本发明化合物在治疗癫痫中的效果显著优于丹参酮IIA,实现了对先导化合物的超越。
具体实施方式
在下文中更详细地描述了本发明以有助于对本发明的理解。
下面实施例中的实验方法,如无特殊说明,均为常规方法。实施例中未注明具体技术或条件者,按照本领域内的文献所描述的技术或条件,或者按照产品说明书进行。
实施例1:
中间体1-b的合成:在氮气保护下,将1-a(4.76g,20mmol)、B2Pin2(6.09g,24mmol)、K2CO3(5.53g,40mmol)、[1,1'-双(二苯基膦)二茂铁]二氯化钯(0.29g,0.4mmol)加入到1,4二氧六环(50mL)中,将上述反应物体系在搅拌下加热回流4h。反应结束后,将反应混合物用乙酸乙酯(100mL)稀释,并用水(2×50mL)洗涤。有机相用无水硫酸镁干燥,过滤,减压蒸馏浓缩滤液,粗品用95%乙醇重结晶,干燥得到中间体1-b(4.67g,收率82%);ESI-MS:286.22[M+H]+。
中间体1-d的合成:在氮气保护下,将1-b(2.85g,10mmol)、1-c(2.09g,12mmol)、K2CO3(2.77g,20mmol)、Pd(PPh3)4(0.23g,0.2mmol)加入到100mL甲苯/乙醇/水(2:1:1)混合溶剂中,将上述反应物体系加热回流5h。反应结束后,自然冷却至室温,加入蒸馏水(100mL),用二氯甲烷(150mL×2)萃取,合并的有机层用无水硫酸镁干燥,过滤,减压蒸馏浓缩滤液,粗品用柱析层(硅胶,流动相石油醚:乙酸乙酯=10:1),干燥,得到中间体1d(2.32g,78%);ESI-MS:298.24[M+H]+。
化合物1的合成:在氮气保护下,将中间体1d(1.49g,5mmol)溶于干燥的二氯甲烷(50mL)中,冷却至在-78℃后,向其中逐滴加入BBr3(二氯甲烷中1.0M,10mmol)。将反应物体系升至0℃,搅拌1.5h,小心地加入水(50mL)。然后将反应物体系在室温下搅拌1h后,再用二氯甲烷(50mL×3)萃取。用饱和碳酸氢钠溶液(50mL)和盐水(50mL)洗涤合并的有机层,用无水硫酸镁干燥,过滤,减压蒸馏浓缩滤液,粗品用柱析层(硅胶,流动相石油醚:乙酸乙酯=30:1~5:1)纯化,干燥,得到化合物1(1.16g,92%)。ESI-MS:252.11[M+H]+;元素分析:理论值,C,71.71;H,3.61;N,5.58;O,19.10;实测值C15H9NO3,C,71.67;H,3.65;N,5.54;O,19.12。1H NMR(400MHz,CDCl3)δ8.90(d,J=7.8Hz,1H),8.84(d,J=7.8,Hz,1H),8.03(d,J=7.8Hz,1H),7.89(d,J=7.9Hz,1H),7.48(5,J=7.8Hz,1H),6.91(s,1H),2.46(s,3H)。
实施例2:
中间体2-b的合成:在氮气保护下,将2-a(3.89g,20mmol)、B2Pin2(6.09g,24mmol)、K2CO3(5.53g,40mmol)、[1,1'-双(二苯基膦)二茂铁]二氯化钯(0.29g,0.4mmol)加入到1,4二氧六环(50mL)中,将上述反应物体系在搅拌下加热回流5h。反应结束后,将反应混合物用乙酸乙酯(100mL)稀释,并用水(2×50mL)洗涤。有机相用无水硫酸镁干燥,过滤,减压蒸馏浓缩滤液,粗品用95%乙醇重结晶,干燥得到中间体2-b(4.52g,收率79%);ESI-MS:287.17[M+H]+。
中间体2-d的合成:在氮气保护下,将2-b(2.86g,10mmol)、1-c(2.09g,12mmol)、K2CO3(2.77g,20mmol)、Pd(PPh3)4(0.23g,0.2mmol)加入到100mL甲苯/乙醇/水(2:1:1)混合溶剂中,将上述反应物体系加热回流7h。反应结束后,自然冷却至室温,加入蒸馏水(100mL),用二氯甲烷(150mL×2)萃取,合并的有机层用无水硫酸镁干燥,过滤,减压蒸馏浓缩滤液,粗品用柱析层(硅胶,流动相石油醚:甲醇=10:1),干燥,得到中间体1d(2.20g,74%);ESI-MS:299.12[M+H]+。
化合物2的合成:在氮气保护下,将中间体2d(1.49g,5mmol)溶于干燥的二氯甲烷(50mL)中,冷却至在-78℃后,向其中逐滴加入BBr3(二氯甲烷中1.0M,10mmol)。将反应物体系升至0℃,搅拌2h,小心地加入水(50mL)。然后将反应物体系在室温下搅拌1h后,再用二氯甲烷(50mL×3)萃取。用饱和碳酸氢钠溶液(50mL)和盐水(50mL)洗涤合并的有机层,用无水硫酸镁干燥,过滤,减压蒸馏浓缩滤液,粗品用柱析层(硅胶,流动相石油醚:乙酸乙酯=15:1~3:1)纯化,干燥,得到化合物2(1.13g,90%)。ESI-MS:253.26[M+H]+;元素分析:理论值C14H8N2O3,C,66.67;H,3.20;N,11.11;O,19.03;实测值,C,66.63;H,3.22;N,11.14;O,19.00。1HNMR(400MHz,CDCl3)δ9.24(d,J=7.8Hz,1H),8.62(d,J=7.8Hz,1H),8.06(d,J=7.9Hz,1H),7.95(d,J=7.9Hz,1H),6.93(s,1H),2.46(s,3H)。
试验例:
1.材料
选取健康的雄性SD大鼠共48只,周龄10周,体质量200~250g。所有大鼠饲养条件一致,均在实验前1周置于同一实验室,自由活动与进食水。试验药物如实施例1和2所制,丹参酮IIA作为对照。大鼠同型半胱氨酸ELISA试剂盒购自赫澎(上海)生物科技有限公司。
2.方法
取40只自由饲养的SD大鼠腹腔注射氯化锂(127mg/kg),经过24h后再腹腔注射戊四氮(35mg/kg)。在注射戊四氮半小后,观察大鼠是否出现咀嚼点头、面肌抽动、四肢阵挛及跌倒等症状。以Racine分级评价为标准,共分为5级:I级:面部阵挛;II级:节律性点头;III级:单侧前肢抽搐;V级:双前肢抽搐;V级:四肢抽搐以及失去平衡、跳跃并跌倒等症状。如出现IV级和V级的痫性发作并持续半小时,可诊断癫痫持续状态。大鼠在建模过程中如持续出现IV~V级表现,提示建模成功,最终建模成功并存活的大鼠有35只,取32只随机分为4组,包括模型组、化合物1、化合物2、丹参酮IIA组,其中化合物1、化合物2、丹参酮IIA组分别灌胃给予40mg/kg·d的药物。另取8只未建模的大鼠作为正常组,正常组和模型组大鼠用等体积的生理盐水(10mL/kg)灌胃。1次/d,连续给药14d。
3.学习记忆能力的测试
使用Mois水迷宫(Use of chronic epilepsy models in antiepileptic drugdiscovery:the effect of topiramate on spontaneous motor seizuresin rats withkainite induced epilepsy.Grabenstatter H L,et al.Epilepsia,2010,46(1):8-14)在高0.5m、直径1.25m、水深0.3m的圆形水池中(水温26.5±0.8℃),在池壁上设置4个不同的标志点,在水池中央设置直径9cm、高28cm的深色平台,平台顶部位于水面下1.5cm处。水迷宫外参照物在训练测试期间保持不变。训练时间为5天,将大鼠分别以4个标志点作为入水点放入池中,记录大鼠游至平台所用的时长。若120秒内大鼠未找到平台,人工则将其引至平台,潜伏期记录为120秒。所有大鼠上台后最长停留30秒,再将其从不同的标志点放入水中进行检测。连续4d进行测试,第5d撤去水中平台,从池壁把大鼠放入水中,记录在60秒的时间内大鼠穿越原平台位置的次数。
4.癫痫发作情况
对模型组和给药组癫痫大鼠分别进行观察,记录大鼠癫痫发作的频率、每次发作持续的时间,并进行组间比较。
5.大鼠海马组织同型半胱氨酸水平检测
取大鼠的大小为1cm×1cm的海马区组织并保存在-50℃的冰箱中。使用前取出,离心取上清液,采用高效液相色谱法,严格按照ELISA试剂盒说明书上的操作步骤进行,对比分析所测的同型半胱氨酸水平。
6.结果分析
采用SPSS22.0统计学软件进行统计处理。采用均数±标准差(—x±s)表示计量资料,采用F检验表示多组间比较,检验水准为α=0.05,P<0.05为差异有统计学意义。
a.总体情况
癫痫模型大鼠发作期表现为兴奋性增高、呼吸快、口吐白沫、站立不稳、四肢抽搐。
b.空间学习记忆能力
从表1的结果可以看出,模型组大鼠逃逸潜伏期时长显著长于正常组,穿台次数显著少于正常组,说明建模成功。而化合物1组、2组大鼠的逃逸潜伏期时长显著短于模型组,也短于丹参酮IIA组,穿台次数则既多于模型组,也多于丹参酮IIA组,这说明化合物1组、2组在改善癫痫大鼠的空间学习记忆能力上具有显著效果,且优于丹参酮IIA。
表1:空间学习记忆能力比较
注:与正常组相比,*P<0.05,**P<0.01,***P<0.001;与模型组相比,#P<0.05,##P<0.01,###P<0.001;与丹参酮IIA组相比,&P<0.05,&&P<0.01
c.癫痫发作情况比较
从表2的结果可以看出,化合物1组、2组大鼠的癫痫发作持续时间和发作频率都显著低于模型组,并且低于丹参酮IIA组,这说明化合物1组、2组在改善癫痫大鼠的癫痫情况上具有显著效果,且优于丹参酮IIA。
表2:癫痫发作情况比较
注:与模型组相比,##P<0.01,###P<0.01;与丹参酮IIA组相比,&&P<0.01
d.同型半胱氨酸水平的比较
同型半胱氨酸是一种含硫氨基酸,是蛋氨酸的中间代谢产物,属于兴奋性氨基酸。同型半胱氨酸作为兴奋性神经递质通过刺激脑内皮细胞神经传导以及提高内皮细胞膜透通性,进一步诱导癫痫发作,加重癫痫症状。从表3的结果可以看出,正常组大鼠的同型半胱氨酸水平较低,但模型组大鼠显著增高,而化合物1和2则有降低同型半胱氨酸水平的作用,且显著优于丹参酮IIA组。
表3:同型半胱氨酸水平的比较
注:与正常组相比,***P<0.001;与模型组相比;#P<0.05,##P<0.01;与丹参酮IIA组相比,&P<0.05
总的来说,本发明化合物具有抑制癫痫,减少发病次数,缩减持续时间的作用,并且能够降低体内同型半胱氨酸的水平,减少神经功能的损伤。
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员,在不脱离本发明方法的前提下,还可以做出若干改进和补充,这些改进和补充也应视为本发明的保护范围。
Claims (9)
1.一种式I化合物或其药学上可接受的盐、溶剂合物:
其中:
X选自CR0、N;
R0表示H、(C1-6)烷基、(C1-6)烷氧基。
R1、R2各自独立地选自H、任选经取代的(C1-6)烷基、任选经取代的(C1-6)烷氧基。
2.根据权利要求1所述的式I化合物或其药学上可接受的盐、溶剂合物,其特征在于,X选自CH、N。
3.根据权利要求1所述的式I化合物或其药学上可接受的盐、溶剂合物,其特征在于,所述任选经取代是指被选自以下基团中的一个或多个取代或未取代:卤素、羟基、氨基。
4.根据权利要求1所述的式I化合物或其药学上可接受的盐、溶剂合物,其特征在于,R1、R2各自独立地选自H、(C1-4)烷基。
5.根据权利要求1所述的式I化合物或其药学上可接受的盐、溶剂合物,其特征在于,R1选自H;R2选自甲基、乙基。
6.根据权利要求1所述的式I化合物或其药学上可接受的盐、溶剂合物,其特征在于,所述化合物选自:
7.一种药物组合物,其包含至少一种根据权利要求1-6中任一项所述的式I化合物或其药学上可接受的盐、溶剂合物。
8.根据权利要求1-6中任一项所述的式I化合物或其药学上可接受的盐、溶剂合物在制备预防或治疗癫痫的药物中的应用。
9.一种制备权利要求1中所述的式I化合物的方法,其包括以下步骤:
将原料a转化为含硼酸酯或硼酸的中间体b,然后与原料c发生偶联反应得到中间体d;中间体d合环成为式I化合物;
其中R1-R2、X如权利要求1中所述,Xa、Xb各自独立地选自氯或溴,Ra、Rb各自独立地选自(C1-4)烷基,RB选自
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310950772.0A CN116987091A (zh) | 2023-07-31 | 2023-07-31 | 用于治疗癫痫发作疾病的药物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310950772.0A CN116987091A (zh) | 2023-07-31 | 2023-07-31 | 用于治疗癫痫发作疾病的药物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116987091A true CN116987091A (zh) | 2023-11-03 |
Family
ID=88527804
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310950772.0A Pending CN116987091A (zh) | 2023-07-31 | 2023-07-31 | 用于治疗癫痫发作疾病的药物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116987091A (zh) |
-
2023
- 2023-07-31 CN CN202310950772.0A patent/CN116987091A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11426419B2 (en) | Compositions and methods for the repair of myelin | |
JP4993523B2 (ja) | 20(s)−プロトパナキサジオールの抗うつ薬製造への使用 | |
EP3458448B1 (en) | Fasn inhibitors for use in treating non-alcoholic steatohepatitis | |
EP1100508A2 (en) | Pharmaceutical combination comprising a tricyclic compound and at least one of zolpidem, zopiclone and brotizolam for treating or preventing sleep disorders | |
AU2020206826B2 (en) | Ketamine pamoate and use thereof | |
CN106866733A (zh) | 左旋美普他酚前药及其制备方法和用途 | |
Zhu et al. | Discovery of a novel series of α-terpineol derivatives as promising anti-asthmatic agents: Their design, synthesis, and biological evaluation | |
KR20100060123A (ko) | 생강 추출물 또는 쇼가올을 포함하는 파킨슨 질환의 예방 또는 치료용 약학 조성물 | |
CN105189446A (zh) | 间苯三酚类衍生物及其在治疗神经退行性疾病中的用途 | |
WO2017035733A1 (zh) | 美金刚与牛蒡子苷元的缀合物及其组合物和用途 | |
BRPI0706865A2 (pt) | método para preparar extrato de shinyleaf yellowhorn e extrato de shinyleaf yellowhorn | |
JP3509637B2 (ja) | 睡眠障害予防治療剤 | |
CN116987091A (zh) | 用于治疗癫痫发作疾病的药物及其制备方法 | |
KR20230159466A (ko) | 구아이안계 세스퀴테르펜 유도체 및 이의 제약 용도 | |
JP7295145B2 (ja) | 神経変性疾患を治療するための医薬及びその使用 | |
CN109988199B (zh) | 红景天苷衍生物及其用途 | |
CN113694055B (zh) | 沉香四醇在制备治疗血管性痴呆疾病的药物中的应用 | |
CN112043700B (zh) | 盐酸去亚甲基四氢小檗碱在制备预防或治疗神经退行性疾病药物中的应用 | |
RU2799454C2 (ru) | Терапевтический препарат для лечения нейродегенеративных заболеваний и его применение | |
CN116143746A (zh) | 预防神经受损及保护神经的化合物、其制法、医药品及其用途 | |
EP2332530A1 (en) | The use of potassium 2-( - hydroxypentyl) benzoate in the manufacture of medicaments for preventing and/or treating senile dementia | |
CN116554144A (zh) | 一种sj系列芳基苯胺类化合物及其制备方法与医药用途 | |
CN117603079A (zh) | 一种治疗疼痛的化合物和组合物 | |
CN111467337A (zh) | 卡达巴木碱在制备抑制脑啡肽酶活性治疗疼痛产品中的用途 | |
IT201800002402A1 (it) | Composto per uso nel trattamento di patologie cerebrali |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |